SciClone to Present at Oppenheimer Healthcare Conference on December 10, 2013

SciClone to Present at Oppenheimer Healthcare Conference on December 10, 2013 
FOSTER CITY, CA -- (Marketwired) -- 12/02/13 --   SciClone
Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm
Blobel, Ph.D., Chief Executive Officer, will present a corporate
overview and business update at the Oppenheimer 24th Annual
Healthcare Conference on Tuesday, December 10, 2013, at 3:20 pm ET at
the Crowne Plaza Hotel in New York.  
To access the live audio webcast of these presentations, please log
on through a link located in the Investor Relations section of
SciClone's website at, under the Calendar of Events
tab. A replay of the webcast will be available one hour after the
conclusion of the live events.  
About SciClone  
SciClone Pharmaceuticals is a revenue-generating, specialty
pharmaceutical company with a substantial commercial business in
China and a product portfolio of therapies for oncology, infectious
diseases and cardiovascular, urological, respiratory, and central
nervous system disorders. SciClone's proprietary lead product,
ZADAXIN(R) (thymalfasin), is approved in over 30 countries and may be
used for the treatment of hepatitis B (HBV), hepatitis C (HCV), and
certain cancers, and as a vaccine adjuvant, according to the local
regulatory approvals. Through its promotion business with
pharmaceutical partners, SciClone markets multiple branded products
in China which are therapeutically differentiated. The Company has
successfully in-licensed products with the potential to become future
market leaders and to drive the Company's long-term growth. SciClone
is a publicly-held corporation based in Foster City, California, and
trades on the NASDAQ Global Select Market under the symbol SCLN. For
additional information, please visit  
Forward-Looking Statements  
This press release contains forward-looking statements regarding
expected financial results and expectations. Readers are urged to
consider statements that include the words "may," "will," "would,"
"could," "should," "might," "believes," "estimates," "projects,"
"potential," "expects," "plans," "anticipates," "intends,"
"continues," "forecast," "designed," "goal," "unaudited,"
"approximately" or the negative of those words or other comparable
 to be uncertain and forward-looking. These statements are
subject to risks and uncertainties that are difficult to predict and
actual outcomes may differ materially. Please also refer to other
risks and uncertainties described in SciClone's filings with the SEC.
All forward-looking statements are based on information currently
available to SciClone and SciClone assumes no obligation to update
any such forward-looking statements. 
SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals
design, the SciClone logo and ZADAXIN are registered trademarks of
SciClone Pharmaceuticals, Inc. in the United States and numerous
other countries. 
Corporate Contacts 
Wilson W. Cheung 
Chief Financial Officer 
Jane Green 
Press spacebar to pause and continue. Press esc to stop.